Rik Ossenkoppele
@rikossenkoppele.bsky.social
Neuroscientist | Alzheimer's disease | Dementia | PET, MRI, Fluid biomarkers | Cognition | Associate Professor at Alzheimercenter Amsterdam & at Lund University.
Reposted by Rik Ossenkoppele
does brain connectivity drive spread of pathological proteins in Alzheimer’s disease?
✨ preprint: www.biorxiv.org/content/10.1...
if the question intrigues you, please read on 🧵⤵️
✨ preprint: www.biorxiv.org/content/10.1...
if the question intrigues you, please read on 🧵⤵️
October 7, 2025 at 8:59 AM
does brain connectivity drive spread of pathological proteins in Alzheimer’s disease?
✨ preprint: www.biorxiv.org/content/10.1...
if the question intrigues you, please read on 🧵⤵️
✨ preprint: www.biorxiv.org/content/10.1...
if the question intrigues you, please read on 🧵⤵️
NEW PREPRINT:
PhD student Ilse Bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and disease severity.
Link @medrxivpreprint: www.medrxiv.org/content/10.1...
PhD student Ilse Bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and disease severity.
Link @medrxivpreprint: www.medrxiv.org/content/10.1...
December 18, 2024 at 11:44 AM
NEW PREPRINT:
PhD student Ilse Bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and disease severity.
Link @medrxivpreprint: www.medrxiv.org/content/10.1...
PhD student Ilse Bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and disease severity.
Link @medrxivpreprint: www.medrxiv.org/content/10.1...
Check out our latest work led by Marie Vermeiren & Ismael Calandri, describing the results of a survey among 268 dementia experts on the future role of Tau PET in the clinic and trials.
Many thanks to all respondents!!!
Link (open access) > dx.doi.org/10.1002/dad2...
Many thanks to all respondents!!!
Link (open access) > dx.doi.org/10.1002/dad2...
November 27, 2024 at 8:36 AM
Check out our latest work led by Marie Vermeiren & Ismael Calandri, describing the results of a survey among 268 dementia experts on the future role of Tau PET in the clinic and trials.
Many thanks to all respondents!!!
Link (open access) > dx.doi.org/10.1002/dad2...
Many thanks to all respondents!!!
Link (open access) > dx.doi.org/10.1002/dad2...